Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.

Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, Simon C.

J Pediatr. 1998 Mar;132(3 Pt 1):543-6.

PMID:
9544920
2.

Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.

Kline MW, Calles NR, Simon C, Schwarzwald H.

Pediatr Infect Dis J. 2000 Nov;19(11):1083-6.

PMID:
11099091
3.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
4.

A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.

Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.

AIDS. 2000 Jul 7;14(10):1375-82.

PMID:
10930152
5.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
6.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
7.

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.

Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.

AIDS. 1999 Jul 30;13(11):F87-93.

PMID:
10449279
8.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
9.

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.

PMID:
9814868
10.

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.

Int J STD AIDS. 2003 May;14(5):350-5.

PMID:
12803944
11.

Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.

Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.

Antivir Ther. 1999;4(4):195-202.

PMID:
10723498
12.

Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.

Villalba N, Gómez-Cano M, Casas E, Soriano V, Valencia E, González-Lahoz J.

AIDS. 1997 Dec;11(15):1896-7. No abstract available.

PMID:
9412717
13.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
14.
15.

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.

Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.

AIDS. 2000 Jun 16;14(9):1181-5.

PMID:
10894282
16.

Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.

Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher H, Bernasconi E, Perrin LH, Yerly S, Hirschel B.

Antivir Ther. 1998;3 Suppl 4:65-7.

PMID:
10723515
17.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group..

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. Erratum in: J Acquir Immune Defic Syndr. 2003 Jan;32(1):116..

PMID:
12473833
18.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
19.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646

Supplemental Content

Support Center